Related Experiment Videos
Effect of long-term celiprolol therapy on haemostasis in essential hypertension
A Okrucká1, J Pechán, H Kratochvílová
1First Department of Medicine, Teaching Hospital, Faculty of Medicine, Comenius University Bratislava, Slovak Republic.
Insights
Celiprolol, an anti-hypertensive drug, was studied for its effects on haemostasis. It was found to reduce platelet aggregation without negatively impacting fibrinolysis or key coagulation inhibitors, suggesting potential cardiovascular benefits.
Area of Science:
- Cardiovascular medicine
- Haematology
- Pharmacology
Background:
- Some antihypertensive drugs can adversely affect haemostasis, potentially accelerating atherogenesis.
- Essential hypertension management requires careful consideration of drug effects on cardiovascular health.
Purpose of the Study:
- To investigate the long-term effects of celiprolol on haemostasis parameters in patients with essential hypertension.
- To assess celiprolol's impact on platelet activity, fibrinolytic activity, and coagulation inhibitors.
Main Methods:
- A study involving 22 patients with essential hypertension undergoing long-term celiprolol therapy (> 2 months).
- A placebo group of 15 patients with essential hypertension was used for comparison.
- Haemostasis parameters, including platelet aggregation, fibrinolytic activity, protein C, and antithrombin III, were measured.
Main Results:
- Celiprolol therapy significantly reduced total platelet aggregation compared to placebo.
- No adverse effects on fibrinolytic activity were observed with celiprolol.
- Coagulation inhibitors, protein C and antithrombin III, remained unaffected by celiprolol treatment.
Conclusions:
- Celiprolol exhibits a platelet-inhibitory tendency with metabolic neutrality, making it a desirable option for hypertension treatment.
- The potentially anti-thrombotic or neutral prothrombotic properties of celiprolol may contribute positively to cardiovascular morbidity outcomes.
Abstract:
Undesirable changes of haemostasis induced by some anti-hypertensive drugs can encourage the acceleration of atherogenesis. Therefore, the changes of haemostasis parameters in 22 patients with essential hypertension under long-term celiprolol therapy (> 2 months) were of interest. In the placebo group of 15 essentially hypertensive patients there were no significant changes in platelet activity. On the other hand, the therapeutic dose of celiprolol was shown to reduce total platelet aggregation, without any harmful effects on fibrinolytic activity and coagulation inhibitors such as protein C and antithrombin III. The metabolic neutrality of celiprolol accompanied by the proven platelet-inhibitory tendency is desirable in the new approach to hypertension treatment. Potentially anti-thrombotic or at least neutral prothrombotic properties of celiprolol may be important in terms of the favourable role of anti-hypertensive drugs in cardiovascular morbidity.